Member Info for BetterX

The SP is gaining traction after Oaktree effectively requesting a takeover. The SP was seriously over-sold anyway and the buyback is continuing so all added stimulants. But at this bargain basement price (earlier this year the SP was >£17) INDV must surely be in the cross-hairs of big pharma. My concern is that the SP is at a fair price when big pharma comes knocking & INDV does not get taken out on the cheap.

If true it is not a surprise. The SP is in bargain basement territory and they are the market leader in a growth area.

Just listened to the live presentation. Sounds like the bottom of the curve has been reached and that there is significant upside. Only 7% of the OUD market is currently being catered for & synthetic opioids that are many times stronger than heroin continue to flood across the USA. The current buy-back is just over half way through so another approx USD 50m or so will be buying back very cheap shares given that they are less than half the price of the recent GBP 17 high.

It has to be in the cross-hairs of big PHARMA given that it's a market leader in a growth market, near a 4 year SP low and has now sorted out many of the major litigation issues.

After today's update even more shares will be able to be bought back! It may be also that the shorts might think about closing which will also significantly impact. I am also of the opinion (maintained over the last 3 years or so) that INDV will be swallowed by large Pharma. But this is my speculation albeit given further credence by the current low SP.

We are all wiser in retrospect and I share an earlier Poster's opinion that the guidance given in Feb 2024 was obviously way out. However, the key consideration now is that given everything is this a good investment at (as I write approx £5.95 to Buy) and my view is that it is a Buy.

I listened to Crossley earlier on the webcast and he kept repeating that this is a transitional period and that there is enormous scope for expansion of the product. I understand that some investors will have lost confidence in his guidance. But even allowing for some over-egging of INDV in his comments this very low price (a 3 year low) together with the positives mentioned above affords a very good opportunity.

As with all investments DYOR etc

Recently started the new $100m share buy-back. At this SP INDV will be able to buy-back TWICE the number of shares that had been buying when SP was £14.

During the Q&A session last week Crossley disclosed that 4 out of 5 new patients opted for Sublocade over Brixadi, Brixadi being Sublocade's biggest rival. He was quite dismissive of Brixadi being a threat to Suiblocade's dominance. He also mentioned that INDV only supplying approx. 6% of the market. Based on this there would appear to be enormous upside for the business.

Crossley & Stejbach both purchased shares

The drift lower this far ahead of US listing will be fund(s) positioning to benefit from the strong upward momentum that will come nearer the date. Once US listing takes effect I expect that INDV will not last that long before being taken out by big pharma.

I also note the comments made by INDV Directors during call following the recent results that referred to dividends. I think that share buy-backs will be replaced by dividends going forward.

Very strong SP move after this update. This together with upcoming primary listing move to USA should be major catalysts over the coming weeks. Share buyback also continuing into August.

GM just confirmed "We expect the transfer of the primary listing will become effective on Thursday June 27, 2024."

Very strong support for this move as one would expect given that the bulk of sales currently comes from USA.

Next Thursday when GM takes place. Should be a formality to get approval.

How long before INDV is purchased by big pharma? Also share buyback is due to continue until August 2024.

Won't be attracted by D4E. The RNS is simply stating that all options are still being considered. This maintains the uncertainty given that options are available which is required when conducting negotiations. The PFC board need to play their hand very shrewdly to get the best deal.

No panic at PFC, quietly getting on with building the business

SP still well behind the curve based on last results. Broker upgrades to come together with share buy-backs until April & a move to USA. I would also throw in takeover speculation as big pharma circles this relative minnow.

INDV continues to storm ahead despite increased competition. The SP was far too low so today's price increase is just partial catch-up. The switch to US main listing is a good move & will generate a lot more interest from US based investors. The big questions are how much longer will INDV remain independent before big PHARMA swallows it and at what price? To answer my own questions, not that long & North of £25.

IMHO and SP currently 20p, do the math.... Lot of shorts to unravel, new contracts in the offing and takeover speculation thrown in for good measure....what a difference a day (and a RNS) makes...

Long term value IMHO is £3+ on the good assumption that PFC gets through this sticky period...So LTH's take heart, there's a lot more to come...

I was not expecting that very positive development.

At today's price that will result in a further approx. 6m shares being bought. This is about 4.3% of total equity.

The buyback starts Monday 20th November.

All LTH's like myself know that PFC is seriously undervalued. When that fully registers with the wider investing community the SP will motor. New contract wins, shorts closing, institutions taking positions, oil price firming all add to the compelling investment case for PFC.